The association of nephrolithiasis with cystic fibrosis

American Journal of Kidney Diseases

Volumn 42, Issue 1 SUPPL. 2, 2003, Pages 1-11

  Gibney, Eric M ^a   Goldfarb, David S ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Calcium oxalate; Cystic fibrosis transmembrane conductance regulator (CFTR); Hyperoxaluria; Nephrolithiasis; Oxalates; Oxalobacter formigenes (O formigenes); Oxaluria; Urinary calculi; Urolithiasis

Indexed keywords

CITRIC ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BACTERIAL COLONIZATION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; HYPEROXALURIA; HYPERURICOSURIA; MEDLINE; NEPHROLITHIASIS; OXALOBACTER FORMIGENES; REVIEW; RISK FACTOR;

EID: 0038724737     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00403-7     Document Type: Article

References (56)

1. Gutknecht DR: Kidney stones and cystic fibrosis. Am J Med 111:83, 2001 (letter)
2. Sidhu H, Hoppe B, Hesse A, et al: Absence of Oxalobacterformigenes in cystic fibrosis patients: A risk factor for hyperoxaluria. Lancet 352:1026-1029, 1998
3. Strandvik B, Hjelte L: Nephrolithiasis in cystic fibrosis. Acta Paediatr 82:306-307, 1993
4. Matthews LA, Doershuk CF, Stern RC, Resnick MI: Urolithiasis and cystic fibrosis. J Urol 155:1563-1564, 1996
5. Chidekel AS, Dolan TF: Cystic fibrosis and calcium oxalate nephrolithiasis. Yale J Biol Med 69:317-321, 1997
6. Hoppe B, Hesse A, Bromme S, Rietschel E, Michalk D: Urinary excretion substances in patients with cystic fibrosis: Risk of urolithiasis? Pediatr Nephrol 12:275-279, 1998
7. Perez-Brayfield MR, Caplan D, Gatti JM, Smith EA, Kirsch AJ: Metabolic risk factors for stone formation in patients with cystic fibrosis. J Urol 167:480-484, 2002
8. Bohles H, Gebhardt B, Beeg T, Sewell AC, Solem E, Posselt G: Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr 140:103-109, 2002
9. Soucie JM, Thun MJ, Coates RJ, McClellan W, Austin H: Demographic and geographic variability of kidney stones in the United States. Kidney Int 46:893-899, 1994
10. Curhan GC, Rimm EB, Willett WC, Stampfer MJ: Regional variation in nephrolithiasis incidence and prevalence among United States men. J Urol 151:838-841, 1994
11. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT: Renal stone epidemiology: A 25-year study in Rochester, Minnesota. Kidney Int 16:624-631, 1979
12. Hiatt RA, Dales LG, Friedman GD, Hunkeler EM: Frequency of urolithiasis in a prepaid medical care program. Am J Epidemiol 115:255-265, 1982
13. Ryall RL, Grover PK, Marshall VR: Urate and calcium stones - Picking up a drop of mercury with one's fingers? Am J Kidney Dis 17:426-430, 1991
14. Stapleton FB, Kennedy J, Nousia-Arvanitakis S, Linshaw MA: Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 295:246-248, 1976
15. Nouisa-Arvanitakis S, Stapleton FB, Linshaw MA, Kennedy J: Therapeutic approach to pancreatic extract-induced hyperuricosuria in cystic fibrosis. J Pediatr 90:302-305, 1977
16. Sack J, Blau H, Goldfarb D, Ben Zaray S, Katznelson D: Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel. Isr J Med Sci 16:417-419, 1980
17. Niessen KH, Wolf A: Studies on the cause of hyperuricosuria in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1:349-354, 1982
18. Wiersbitzky S, Ballke EH, Wolf E, Paul W: Uric acid serum concentrations in CF-children after pancreatic enzyme supplementation. Padiatr Grenzgeb 28:171-173, 1989
19. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L: Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 34:158-166, 1994
20. Dharmsathaphorn K, Freeman DH, Binder HJ, Dobbins JW: Increased risk of nephrolithiasis in patients with steatorrhea. Dig Dis Sci 27:401-405, 1982
21. Dobbins JW, Binder HJ: Importance of the colon in enteric hyperoxaluria. N Engl J Med 296:298-301, 1977
22. Bohles H, Michalk D: Is there a risk for kidney stone formation in cystic fibrosis? Helv Paediatr Acta 37:267-272, 1982
23. Turner MA, Goldwater D, David TJ: Oxalate and calcium excretion in cystic fibrosis. Arch Dis Child 83:244-247, 2000
24. Davidson AGF: Gastrointestinal and pancreatic disease in cystic fibrosis, in Hodson ME, Geddes DM (eds): Cystic Fibrosis (ed 2). New York, NY, Arnold, 2000, pp 261-288
25. Bentur L, Kerem E, Couper R, et al: Renal calcium handling in cystic fibrosis: Lack of evidence for a primary renal defect. J Pediatr 116:556-560, 1990
26. Aris RM, Lester GE, Dingman S, Ontjes DA: Altered calcium homeostasis in adults with cystic fibrosis. Osteoporos Int 10:102-108, 1999
27. Lark RK, Lester GE, Ontjes DA, et al: Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr 73:602-606, 2001
28. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ: Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 135:601-610, 1999
29. Moxey-Mims MM, Stapleton FB: Hypercalciuria and nephrocalcinosis in children. Curr Opin Pediatr 5:186-190, 1993
30. Shaer AJ: Inherited primary renal tubular hypokalemic alkalosis: A review of Gitelman and Bartter syndromes. Am J Med Sci 322:316-332, 2001
31. Ronnefarth G, Misselwitz J: Nephrocalcinosis in children: A retrospective survey. Members of the Arbeitsgemeinschaft fur padiatrische Nephrologie. Pediatr Nephrol 14:1016-1021, 2000
32. Katz SM, Krueger LJ, Falkner B: Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med 319:263-266.
33. Couper R, Bentur L, Kilbourn JP, Wolf P: Immunoreactive calmodulin in cystic fibrosis kidneys. Aust N Z J Med 23:484-488, 1993
34. Schindler R, Radke C, Paul K, Frei U: Renal problems after lung transplantation of cystic fibrosis patients. Nephrol Dial Transplant 16:1324-1328, 2001
35. Foskett JK: C1C and CFTR chloride channel gating. Annu Rev Physiol 60:689-717, 1998
36. Thakker RV: Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 57:787-793, 2000
37. Scheinman SJ, Cox JP, Lloyd SE, et al: Isolated hypercalciuria with mutation in CLCN5: Relevance to idiopathic hypercalciuria. Kidney Int 57:232-239, 2000
38. George AL Jr, Bianchi L, Link EM, Vanoye CG: From stones to bones: The biology of C1C chloride channels. Curt Biol 11:R620-R628, 2001
39. Reungjui S, Prasongwatana V, Premgamone A, Tosukhowong P, Jirakulsomchok S, Sriboonlue P: Magnesium status of patients with renal stones and its effect on urinary citrate excretion. BJU Int 90:635-639, 2002
40. Bar-Or O, Blimkie CJ, Hay JA, MacDougall JD, Ward DS, Wilson WM: Voluntary dehydration and heat intolerance in cystic fibrosis. Lancet 339:696-699, 1992
41. Kriemler S, Wilk B, Schurer W, Wilson WM, Bar-Or O: Preventing dehydration in children with cystic fibrosis who exercise in the heat. Med Sci Sports Exerc 31:774-779, 1999
42. Trinchieri A, Mandressi A, Luongo P, Rovera F, Longo G: Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones. Scand J Urol Nephrol 26:379-386, 1992
43. Krebs NF, Westcott JE, Arnold TD, et al: Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 48:256-261, 2000
44. Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV: Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 116:455-460, 1986
45. Allison MJ, Cook HM: Oxalate degradation by microbes of the large bowel of herbivores: The effect of dietary oxalate. Science 212:675-676, 1981
46. Allison MJ, Dawson KA, Mayberry WR, Foss JG: Oxalobacter formigenes gen nov, sp nov: Oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141:1-7, 1985
47. Kwak C, Jeong BC, Lee JH, Kim HK, Kim EC, Kim HH: Molecular identification of Oxalobacter formigenes with the polymerase chain reaction in fresh or frozen fecal samples. BJU Int 88:627-632, 2001
48. Sidhu H, Holmes RP, Allison MJ, Peck AB: Direct quantification of the enteric bacterium Oxalobacter formigenes in human fecal samples by quantitative competitive-template PCR. J Clin Microbiol 37:1503-1509, 1999
49. Daniel SL, Hartman PA, Allison MJ: Intestinal colonization of laboratory rats with Oxalobacter formigenes. Appl Environ Microbiol 53:2767-2770, 1987
50. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB: Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacterformigenes. J Urol 166:1487-1491, 2001
51. Sidhu H, Schmidt ME, Cornelius JG, et al: Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10:S334-S340, 1999 (suppl 14)
52. Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS: Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 68:3841-3847, 2002
53. Freel RW, Hatch M, Vaziri ND: Conductive pathways for chloride and oxalate in rabbit ileal brush-border membrane vesicles. Am J Physiol 275:C748-C757, 1998
54. Hokama S, Honma Y, Toma C, Ogawa Y: Oxalate-degrading Enterococcusfaecalis. Microbiol Immunol 44:235-240, 2000
55. Campieri C, Campieri M, Bertuzzi V, et al: Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 60:1097-1105, 2001
56. Cystic Fibrosis Foundation: Patient Registry 2001, in Annual Report. Bethesda, MD, Cystic Fibrosis Foundation, 2002